Basilea Pharmaceutica AG
Basilea Pharmaceutica AG
Your view on BPMUF
Overview
What the company does, where it operates, and who runs it.
About Basilea Pharmaceutica AG
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Veitch
- Headquarters
- Grenzacherstrasse 487, Allschwil, CH
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Veitch
- Headquarters
- Grenzacherstrasse 487, Allschwil, CH
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives.
It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan.
The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia.
In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Basilea Pharmaceutica AG, and the rating behind it. BPMUF last traded at $71.00, 15.7× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Basilea Pharmaceutica AG. Starting points for Basilea Pharmaceutica AG: P/E 15.7, EPS $4.23, beta 0.45 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Basilea Pharmaceutica AG. Basilea Pharmaceutica AG does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Basilea Pharmaceutica AG. Trailing twelve-month EPS for Basilea Pharmaceutica AG stands at $4.23. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Basilea Pharmaceutica AG. Basilea Pharmaceutica AG has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Basilea Pharmaceutica AG valued side by side against its closest peers. Basilea Pharmaceutica AG is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Basilea Pharmaceutica AG, and how their positions are changing. At a $871.3M market value, institutional positions materially move Basilea Pharmaceutica AG's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Basilea Pharmaceutica AG executives and directors. Shares of Basilea Pharmaceutica AG have traded between $47.50 and $74.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Basilea Pharmaceutica AG. Basilea Pharmaceutica AG is a $871.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Basilea Pharmaceutica AG. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Basilea Pharmaceutica AG. Coverage tracks Basilea Pharmaceutica AG within Biotechnology (Healthcare). Press releases and market coverage, newest first.